CalproQuest survey may increase pretest probability for a positive calprotectin test
TUESDAY, Feb. 5, 2019 (HealthDay News) — The CalproQuest, an eight-item questionnaire, is a feasible instrument for assessing patients for inflammatory bowel disease in primary care settings, according to a study published in the February issue of the Journal of Evaluation in Clinical Practice.
Corinne Chmiel, P.D., Dr.Med., from the University of Zurich, and colleagues evaluated the feasibility and acceptability of CalproQuest for at least two weeks among 95 patients with unspecific gastrointestinal complaints who were seen in primary care settings.
The researchers found that 54.7 percent of CalproQuests were positive, with 41.1 percent of patients fulfilling two major criteria and 13.7 percent having one major and at least two minor criteria. General practitioners completed questionnaires on feasibility, which 87.4 percent assessed positively. Similarly, patient-reported acceptance was high (86.3 percent).
“Further prospective studies concerning validity and cost-effectiveness of a combined use with the calprotectin test in this setting are necessary,” the authors write.
Urine Cell-Free RNA Shows Promise as Biomarker for Bladder Cancer
Age-, Joint-Specific Ultrasound Reference Values Set for Healthy Joints
Serum 25(OH)D May Serve as Biomarker of Disease Activity in IBD
IBD Not Linked to Risk for Hypertensive Disorders of Pregnancy Overall
Low Levels of Placental Growth Factor in Pregnancy Linked to Subsequent ADHD in Offspring
Recommendations Issued for Use of Incretin-Based Meds in Pregnancy
Pregnancy Complications Linked to Subsequent Risk for Cardiometabolic-Renal Conditions
Isometric Exercise Training Three Times a Week Preserves Cardiovascular Benefits